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Abstract
We analysed a phenotypically well-characterised sample of 450 schziophrenia patients and 605 controls for rare non-
synonymous single nucleotide polymorphisms (nsSNPs) in the GRM1 gene, their functional effects and family segregation.
GRM1 encodes the metabotropic glutamate receptor 1 (mGluR1), whose documented role as a modulator of neuronal
signalling and synaptic plasticity makes it a plausible schizophrenia candidate. In a recent study, this gene was shown to
harbour a cluster of deleterious nsSNPs within a functionally important domain of the receptor, in patients with
schizophrenia and bipolar disorder. Our Sanger sequencing of the GRM1 coding regions detected equal numbers of nsSNPs
in cases and controls, however the two groups differed in terms of the potential effects of the variants on receptor function:
6/6 case-specific and only 1/6 control-specific nsSNPs were predicted to be deleterious. Our in-vitro experimental follow-up
of the case-specific mutants showed that 4/6 led to significantly reduced inositol phosphate production, indicating impaired
function of the major mGluR1signalling pathway; 1/6 had reduced cell membrane expression; inconclusive results were
obtained in 1/6. Family segregation analysis indicated that these deleterious nsSNPs were inherited. Interestingly, four of the
families were affected by multiple neuropsychiatric conditions, not limited to schizophrenia, and the mutations were
detected in relatives with schizophrenia, depression and anxiety, drug and alcohol dependence, and epilepsy. Our findings
suggest a possible mGluR1 contribution to diverse psychiatric conditions, supporting the modulatory role of the receptor in
such conditions as proposed previously on the basis of in vitro experiments and animal studies.
Citation: Ayoub MA, Angelicheva D, Vile D, Chandler D, Morar B, et al. (2012) Deleterious GRM1 Mutations in Schizophrenia. PLoS ONE 7(3): e32849. doi:10.1371/
journal.pone.0032849
Editor: Neil R. Smalheiser, University of Illinois-Chicago, United States of America
Received September 15, 2011; Accepted February 3, 2012; Published March 20, 2012
Copyright:  2012 Ayoub et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by the National Health and Medical Research Council project grants #37580400 and #37580900 to AJ and LK. KDGP is
supported by an Australian Research Council Future Fellowship (FT100100271). PMV is supported by the Australian National Health and Medical Research Council.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: luba.kalaydjieva@uwa.edu.au (LK); kpfleger@waimr.uwa.edu.au (KDGP)
. These authors contributed equally to this work.
Introduction
Metabotropic glutamate receptor 1 (mGluR1), the protein
product of the GRM1 gene, is a Family C G protein-coupled
receptor (GPCR) belonging to Group I of mGluRs, along with
mGluR5. In addition to the seven transmembrane helical structure,
conserved throughout all GPCRs, Class C receptors are also
characterised by a large bi-lobed ligand binding domain linked to
the transmembrane region by a cysteine-rich domain, as well as a
large intracellular C-terminal tail [1]. mGluR1 is predominantly
expressed post-synaptically in neurons of the hippocampus,
hypothalamus, thalamus, amygdala, basal ganglia, cerebellum and
spinal cord [2–5], where it modulates N-methyl-D-aspartate
(NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) and c-aminobutyric acid (GABA) receptor activity [6].
Pharmacological activation of mGluR1, leading to activation of
phospholipase C and consequent phosphoinositide hydrolysis, has
been shown to facilitate NMDA receptor responses in cortical
neurons and the CA3 area of the hippocampus [6–9]. The
receptor also plays a critical role in synaptic plasticity, memory
and learning [10–13] by regulating local dendritic protein
synthesis in functional interaction with the fragile X mental
retardation protein (FMRP) [14–18]. Hypofunction/dysregulation
of glutamatergic signalling is one of the dominant concepts of
schizophrenia pathogenesis, originally based on observations that
NMDA receptor antagonists can induce psychotic symptoms and
cognitive deficits closely resembling those in schizophrenia, and
later supported by findings of altered NMDA receptor subunit
composition and changes in NMDA receptor-related postsynaptic
proteins in schizophrenia brains [19–23]. While the experimen-
tally documented mGluR1 functions could be related to the
dysfunctional glutamatergic signalling and impaired synaptic
plasticity underlying the cognitive deficit of affected individuals
[19–23], GRM1 has not emerged as a schizophrenia candidate
gene from linkage and association studies. Until recently, its
possible involvement was suggested only by observations of altered
expression levels in post-mortem schizophrenia brains [24,25],
where increased mGluR1 expression in the prefrontal cortex has
been interpreted as a compensatory change to the NMDA
receptor hypofunction [24], as well as by the deficits in
sensorimotor gating (prepulse inhibition of acoustic startle) in
Grm1 knock-out mice [26] similar to those seen in schizophrenia
patients.
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In a recent study, Frank et al. [27] examined common variants
in multiple genes encoding post-synaptic density proteins, in
parallel with a search for rare mutations specifically targeting
‘‘hub’’ genes involved in glutamate neurotransmission. Sequencing
analysis in 503 schizophrenia and 263 bipolar cases, and 538
controls identified an unusual clustering of rare non-synonymous
variants in GRM1, in the small gene region encoding the
functionally important cysteine-rich domain, which mediates
receptor dimerization and activation upon ligand binding [27].
This was the first study to implicate directly rare GRM1 mutations
in the pathogenesis of psychotic illness.
Here, we examined the occurrence, inheritance and functional
effects of rare GRM1 nsSNPs in a clinically and neurocognitively
characterised sample of 450 schizophrenia cases and 605 controls.
Materials and Methods
Ethics Statement
All subjects had provided written informed consent and the
study was approved by the Human Research Ethics Committee of
The University of Western Australia. The capacity of the patients
to provide informed consent was established through a structured
interview, and was also confirmed by their treating psychiatrists.
Subjects
The cases, 348 male and 102 female patients of European
descent (,75% Anglo-Irish), were recruited from consecutive
admissions to psychiatric hospitals or community mental health
centres as part of the West Australian Family Study of
Schizophrenia (WAFSS). Diagnostic assessment was based on
standardized interviews using the Schedules for Clinical Assess-
ment in Neuropsychiatry [28] and scored with the OPCRIT
algorithm [29]. Videorecorded interviews and clinical charts were
independently reviewed by two senior clinicians who assigned
consensus research ICD-10 and DSM-IV diagnoses. The 605
healthy controls included 265 WAFSS participants, recruited by
random sampling from local telephone directories or among Red
Cross blood donors; the remainder were samples from the ‘‘Aussie
Normals’’ collection (http://www.neura.edu.au/content/aussie-
normals).
All WAFSS participants completed a battery of neurocognitive
tests as described [30]. In brief, these included pre-morbid IQ
(National Adult Reading Test, NART); current IQ (Shipley
Institute of Living Scale, SILS); verbal memory (Rey’s Adult
Verbal Learning Test immediate and delayed word recall,
RAVLT-IW and RAVLT-DW); and sustained attention (Contin-
uous Performance Task identical pairs and degraded stimulus,
CPTip and CPTds). Performance data from the multiple
neurocognitive domains were integrated into a cognitive deficit
(CD) and cognitively spared (CS) composite continuous trait, using
a grade of membership (GoM) model [30–32]. Based on a
statistically defined cut-off in the scores, patients were assigned to a
CD or CS cluster, and a small residual non-CD/non-CS group.
Re-sequencing of the GRM1 gene
The eight coding exons and at least 100 bp of flanking intronic
sequences of the longest GRM1 transcript (NM_000838), a total of
5780 bp (3585 bp of which was coding), were PCR-amplified from
genomic DNA extracted from fresh blood using ten amplicons.
Primers (Table S1) were designed using the Primer3 software
(http://frodo.wi.mit.edu/primer3/). PCR reactions and Sanger
sequencing of both strands were performed at the Australian
Genome Research Facility (Brisbane, Queensland) in a 384-well
plate format following standard procedures. The sequencing data
were analysed with the Sequencher 4.8 software, followed by
visual examination of the identified variants in the chromato-
grams. Technical replication of all identified novel changes in the
coding sequence was done by Sanger sequencing of both DNA
strands in newly aliquoted DNA samples.
Bioinformatics analysis of detected sequence variants
The potential effect of non-synonymous sequence variants on
protein structure and function was evaluated using four different
prediction programs: PolyPhen2 [33] (http://genetics.bwh.
harvard.edu/pph2/); SIFT [34] (http://sift.jcvi.org/); Pmut [35]
(http://mmb.pcb.ub.es/PMut/); and PhD-SNP [36] (http://
gpcr2.biocomp.unibo.it/cgi/predictors/PhD-SNP/PhD-SNP.cgi).
Intronic and coding synonymous variants were assessed for
potential effects on splicing using Human Splicing Finder [37]
(http://www.umd.be/HSF/) and ESEFinder [38] (http://rulai.
cshl.edu/tools/ESE/).
Family studies
The families of patients carrying nsSNPs were approached
through the proband to obtain informed consent for additional
studies. During a home visit by members of the research team,
family members completed diagnostic interviews and neurocogni-
tive tests. Data on family history of neuropsychiatric disorders
were obtained through interviews with key informants. The nsSNP
segregation pattern was analysed by sequencing the respective
exons in the available DNA samples of first degree relatives.
Plasmid construction and reagents for in vitro analyses of
mGluR1 function
Wild-type (wt) GRM1 cDNA synthesis, mutagenesis introducing
the variants of interest, N-terminal tagging with a Flag tag, and
subcloning into the pcDNA3.1 vector was performed by
GENEART (www.geneart.com; Regensburg, Germany). The
plasmid coding for the glutamate transporter EAAC1 (gene
symbol SLC1A1) was generously provided by Dr. Jean-Philippe
Pin (IGF Montpellier, France). Quisqualic acid (Quisqualate) was
from Tocris Bioscience (Ellisville, Missouri, USA). The purified
Mouse Anti-mGluR1 antibody was purchased from BD Trans-
duction Laboratories (Franklin Lakes, NJ, USA).
Cell culture and transfection
COS-7 cells were maintained at 37uC, 5% CO2 in complete
medium (Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 0.3 mg/ml glutamine, 100 IU/ml penicillin, and 100 mg/ml
streptomycin) supplemented with 10% fetal calf serum (FCS)
(GIBCO BRL, Carlsbad, CA). Transient transfections were
carried out in a 96-well plate using GeneJuice (Merck, Kilsyth,
Australia). Briefly, for each well, 150 ng of mGluR1-coding
plasmid (wild-type and mutants) and 100 ng of EAAC1-coding
plasmid were incubated for 20 minutes at room temperature with
a mix of 0.5 ml of GeneJuice and 49.5 ml of serum-free DMEM
(pre-incubated at room temperature for 5 minutes). Cells (105 in
150 ml/well) in DMEM supplemented with 10% FCS were then
incubated with the final DNA-GeneJuice mix (50 ml/well). 24 h
post-transfection, the medium was replaced by DMEM-Glutamax
(GIBCO BRL, Carlsbad, CA).
Inositol monophosphate (IP1) production measurements
IP1 accumulation was measured in white 96-well plates (10
5
cells/well) using the IP-One Tb kit (Cisbio Bioassays, Bagnol sur
Ceze, France). The cells were incubated for 45 minutes at 37uC in
the stimulation buffer (10 mM HEPES, pH 7.4, 1 mM CaCl2,
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0.5 mM MgCl2, 4 mM KCl, 146 mM NaCl, 5.5 mM glucose,
and 50 mM LiCl) with or without 10 mM of the glutamate agonist
Quisqualate used to activate the receptor. The cells were then
lysed by adding the HTRFH assay reagents, the Terbium
Cryptate-labeled anti-IP1 antibody, and the d2-labeled IP1 analog
(diluted in the conjugated lysis buffer containing 1% Triton X-
100). The assay was incubated for 1 hour at room temperature.
After excitation at 340 nm, Terbium Cryptate fluorescence and
the time-resolved FRET signal were measured at 620 and 665 nm
respectively using an EnVision 2102 multilabel plate reader
(PerkinElmer, Glen Waverley, Victoria, Australia).
Enzyme-linked immunosorbent assay (ELISA)
COS-7 cells were washed once with phosphate-buffered saline
(PBS), fixed for 10 minutes at room temperature with 4%
paraformaldehyde and blocked with PBS containing 1% FCS.
The receptor labelling was performed by incubation for
30 minutes at room temperature with 250 ng/ml (dilution
1:1000) of purified mouse Anti-mGluR1 antibody in PBS
containing 1% FCS. The cells were washed three times and
incubated for 30 minutes with 0.5 mg/ml of horseradish peroxi-
dase-conjugated anti-mouse secondary antibody (Amersham
Pharmacia, NJ, USA) in PBS containing 1% FCS and washed
three times again. For the detection of bound antibody, we used
10 ml/well of SuperSignal substrate (Pierce, Rockford, IL, USA) in
90 ml of PBS. Luminescence was measured in a VictorLight plate
reader (PerkinElmer).
Statistical analysis of functional data
Individual Quisqualate-induced IP1 responses and ELISA
signals were expressed as percentages of the corresponding values
obtained with wt mGluR1 in the same experiment. Mean
percentages from four independent experiments carried out in
triplicate were used for statistical analysis using a one sample t test
comparing to the expected value of 100% (Prism 5 software,
GraphPad, La Jolla, CA, USA).
Results
High quality sequencing data were obtained for 1032 of the
1055 samples (443 cases and 589 controls) with minor variation in
the numbers for the different GRM1 exons (from 437 to 447 for
cases and from 578 to 594 for controls).
General characteristics of the detected variation
We identified a total of 47 variants, all of which were nucleotide
substitutions, mostly (32/47) occurring in a single individual in the
heterozygous state. 41 were coding SNPs and, of these, 16 were
non-synonymous variants (Table S2).
The detected changes were spread across the GRM1 gene, with
a significant proportion in the 39 end (Table S2, Figure 1a). The
overall diversity in the coding sequence was largely accounted for
by the variable exon 8, which harboured 46% (19/41) of all coding
and 44% (7/16) of the non-synonymous mutations, including the
five known highly polymorphic coding SNPs: S993P, K931K,
Figure 1. Distribution of the coding mutations in the GRM1 gene and the encoded mGluR1 protein. (a) All coding mutations relative to
gene structure, with GRM1 exons 1 to 8 shown in alternating shaded bars. Top panel: changes found in patients; bottom panel: changes found in
controls. Colour coding: red - rare missense variants; blue - common missense variants (MAF.1%), black- synonymous variants. (b) Non-synonymous
coding changes relative to the mGluR1 receptor protein domains (shown as grey bars). Colour coding: red circles – case-specific, green circles –
control specific, red circles with green outline – detected in cases as well as controls. Mutation predicted by bioinformatics programs to have a
deleterious effect on protein function are italicised and underlined.
doi:10.1371/journal.pone.0032849.g001
GRM1 Mutations in Schizophrenia
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32849
G1056G, P1071P and P1165P. GRM1 exon 8 encodes most of the
cytoplasmic C terminal tail of mGluR1, which mediates its
interactions with multiple intracellular protein partners [39].
Potential deleterious effects of the detected variants
Neither the intronic nor any of the synonymous coding
mutations were predicted by Human Splicing Finder and
ESEfinder to result in aberrant splicing.
Half of the nsSNPs (8/16), both rare and common, were
classified as benign by all bioinformatics programs used for the
prediction of potential functional effects (Table 1). The predictions
for the remaining variants differed significantly between programs
(Table 1), therefore further consideration was given to those
classified as deleterious either with a high probability score by any
program, or by more than one program regardless of the score.
The best agreement was seen for the A683E mutation, carried by a
single individual, and for the known SNP rs41305288 (P729T),
present in the heterozygous state in 17 subjects - both were
predicted to be deleterious by 3 of the 4 programs.
GRM1 sequence variation relative to affection status
We identified nine case-specific coding variants (synonymous
and non-synonymous, Table S2), i.e. 2% of schizophrenia patients
carried one. None are listed in dbSNP build 134, which
incorporates data on rare mutations detected in the ‘‘1000
genomes’’ project. The number of control-specific coding variants
was 21 (13 also listed in dbSNP 134), i.e. 3.6% of controls had one
(p = 0.19).
The nsSNPs were also equally distributed between cases and
controls (Figure 1b), with six detected in each group (1.3% of cases
and 1% of controls, p = 0.57). SNP rs41305288 (P729T) was
present in the heterozygous form in 6 cases (1.35%) and 11
controls (1.87%) (p = 0.46).
The only marginally significant difference apparent from these
analyses concerned the distribution of rare potentially deleterious
nsSNPs (Table 1, Figure 1b). All six in the schizophrenia group
and only one in the controls were predicted to affect receptor
function, i.e. 1.35% of affected subjects and 0.17% of controls
carried a potentially harmful mutation (p= 0.047). The case-
specific deleterious nsSNPs occurred in different parts of the gene,
with one resulting amino acid substitution in the mGluR1 ligand-
binding domain, two in the transmembrane region (including
intracellular loop 2) and three in the proline-rich domain of the
intracellular C-terminal tail.
Phenotypes and family segregation patterns
The affected subjects carrying potentially deleterious nsSNPs
in GRM1 were distributed between diagnostic categories and
neurocognitive clusters (Figure 2). Four had been classified as
schizophrenia (mutations F122L, A683E, P1014S and P1015A),
and two as schizoaffective disorder (mutations Y632H and P970L).
The schizophrenia patients, carrying mutations A683E and
P1014S, had been assigned to the cognitive deficit (CD) cluster,
the remaining cases belonged to the cognitively spared cluster.
Additional information on family history and current status of
1st-degree relatives was collected, and genotyping performed for
Table 1. Non-synonymous mutations and their predicted effects on mGluR1 function.
Mutation Protein domain# Bioinformatics prediction programs
PolyPhen-2 SIFT PMut PhD-SNP
Cases only
F122L LBD probably 0.950 tolerated 0.15 neutral-5 disease 6
Y632H TM2 probably 0.999 tolerated 1.00 neutral-5 disease 2
A683E ICL2 probably 0.998 tolerated 0.10 pathological-8 disease 6
P970L PRD benign 0.021 deleterious 0.03 pathological-2 neutral 7
P1014S PRD benign 0.001 deleterious 0.03 neutral-5 neutral 8
P1015A PRD probably 0.986 tolerated 0.10 neutral-3 neutral 8
Controls only
I130V LBD benign 0.004 tolerated 0.56 neutral-9 neutral 7
K276T LBD benign 0.180 tolerated 0.09 neutral-3 neutral 6
D446N LBD possibly 0.463 tolerated 0.46 neutral-4 neutral 8
T548M CRD probably 0.996 tolerated 0.14 neutral-4 neutral 8
P1069L* PRD benign 0.001 tolerated 0.51 pathological-1 neutral 6
P1072A PRD benign 0.019 tolerated 0.81 neutral-6 neutral 7
Cases & controls
P729T* ECL2 probably 0.999 deleterious 0.01 neutral-8 disease 6
G884E* Cter benign 0.023 tolerated 0.42 pathological-4 neutral 2
V929I* Cter benign 0.001 tolerated 0.00 neutral-9 neutral 6
S993P* PRD benign 0.009 tolerated 0.08 neutral-7 neutral 9
Prediction programs’ scoring: PolyPhen-2 Bayes posterior probability that mutation is deleterious;
SIFT scores ,0.05 indicate deleterious effect; PMut and PhD-SNP reliability of predictions 1-low, 9-high.
*known SNPs.
#Protein domains: LBD, ligand-binding domain; CRD, cysteine-rich domain; TM, transmembrane domain; ICL, intracellular loop; ECL, extracellular loop; Cter, C terminal
tail; PRD, proline-rich domain in C terminal tail.
doi:10.1371/journal.pone.0032849.t001
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five potentially deleterious nsSNPs (all except P1015A). In addition
to the probands with clinically diagnosed schizophrenia, 4 of these
5 families had multiple cases of other neuropsychiatric disorders,
such as epilepsy, Asperger syndrome, anxiety, depression and
substance abuse (Figure 2).
None of the five nsSNPs genotyped in family members was a de
novo mutation, all were inherited. The family segregation analysis
(Figure 2) showed that, in addition to the schizophrenia probands,
GRM1 mutations (e.g. F122L, Y632H and P970L) were also
present in 1st degree relatives with other neuropsychiatric
conditions not limited to psychosis, suggesting a pleiotropic effect.
F122L, A683E were also found in relatives completely free of
psychiatric morbidity and with normal cognitive function, pointing
to incomplete penetrance.
Functional data
The major mGluR1-mediated G protein signalling pathway,
resulting in production of inositol phosphates, was examined in
COS-7 cells transiently expressing wild-type or mutant mGluR1.
The utilized assay measured the production of inositol phosphate
(IP1) in response to treatment with the glutamate agonist
Quisqualate. To avoid saturation and desensitization of the
receptor by endogenously produced glutamate, the cells were co-
transfected with the EAAC1 transporter, the in vivo neuronal
function of which is to terminate the post-synaptic action of
glutamate by removing it from the synaptic cleft. We compared
IP1 production in the cells expressing wild-type mGluR1 to that in
cells expressing the case-specific non-synonymous changes and the
known P729T polymorphism. The control-specific T548M was
not included in these analyses as it was previously shown in a
similar experimental design to have no functional consequences
[27].
These analyses revealed a dramatic reduction in signalling
efficacy caused by four of the mGluR1 mutants: F122L, A683E,
P970L and P1015A compared to the wild-type receptor
(Figure 3a). In contrast, no significant effect on inositol phosphate
signalling efficacy was observed with the Y632H and P1014S
mutations, or the P729T polymorphism in this in vitro cell system.
Note that we did not see any specific cAMP signalling response
resulting from mGluR1 activation by Quisqualate from any of the
receptors, including wild-type (data not shown).
Since the observed signalling differences could be due to
differing plasma membrane expression, we compared levels of the
mutant receptors at the cell surface relative to wild-type. We
performed an ELISA assay, using an anti-mGluR1 antibody, in
parallel to the functional IP1 assay. We found that none of the
mutations that affected signalling efficacy (F122L, A683E, P970L
or P1015A) significantly affected plasma membrane expression.
Thus, the observed decrease in Quisqualate-induced IP1 produc-
tion with these mutations can be attributed to a reduction in
mGluR1 signalling function in these cells. The P1014S mutation
that did not affect signalling efficacy did however result in a
significant reduction in cell surface expression by 33% (Figure 3).
The Y632H mutation reduced cell surface expression by 50%, but
this was not statistically significant due to high experimental
variability (n = 4). The P729T polymorphism did not significantly
affect either signalling efficacy or cell surface expression.
Discussion
The modest success of genome-wide association studies, the
disputed issue of ‘‘missing heritability’’, and the advent of
increasingly affordable large-scale sequencing technologies have
shifted the paradigm in genetic studies of mental illness from the
‘‘common disease – common variants’’ concept to multiple rare
Figure 2. Structure, neuropsychiatric morbidity and mutation segregation in families of schizophrenia probands with deleterious
GRM1 variants.
doi:10.1371/journal.pone.0032849.g002
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mutations in diverse genes, or a combination of the two, ultimately
converging to a manageable number of pathways of molecular
pathogenesis. Two recent studies [40,41] carried out exome
sequencing in small numbers of sporadic schizophrenia cases and
found a predominance of de novo mutations in multiple genes, most
of which have not been implicated in schizophrenia previously,
while others targeted candidate genes encoding synaptic proteins
[42] or ‘‘hub’’ genes involved in glutamate signaling [27]. In this
study, we performed Sanger sequencing of a single gene, GRM1, in
a sample of well-characterized schizophrenia cases and controls
from the West Australian Family Study of Schizophrenia. While
the detected rare nsSNPs showed no difference between cases and
controls in terms of overall frequency, there was an excess of
mutations with a predicted deleterious effect on receptor function
in the schizophrenia group. Bioinformatics predictions often
produce divergent results [43], and none of our case-specific
variants was unanimously predicted to be deleterious. Our in vitro
analyses of the mGluR1receptor function of the case-specific
mutants aimed to resolve these inconsistencies and possibly clarify
genotype-phenotype correlations. P729T was also included, as a
polymorphism with strong deleteriousness predictions yet no
association with disease (allele frequencies 0.014 in cases and 0.019
in controls). Experimental verification of the predictions for the
control-specific nsSNPs was considered to be outside the scope of
this study. Moreover, most were classified as benign with very
good agreement between the different bioinformatics programs.
In order to obtain functional data, we performed in vitro assays
where we expressed wild-type and mutant mGluR1 in COS-7
cells. We analysed the major mGluR1 inositol phosphate signalling
pathway after stimulation of the receptor with a glutamate agonist.
To avoid receptor desensitization as a consequence of continuous
stimulation by background glutamate, the cells were co-transfected
with the glutamate EAAC1 transporter. The analysis revealed
reduction in inositol phosphate production after receptor stimu-
lation for 4 of the 6 case-specific mutations. The observed decrease
was not due to reduced expression of the mutant proteins on the
cell membrane and thus can be classified as genuine reduction of
signalling function caused by the F122L, A683E, P970L and
P1015A mutations. Although there are obvious differences
between a COS-7 cell in an in vitro cell culture system and a
neuron in a living human brain, the observed reduction in
receptor signalling capacity indicates a potential mechanism by
which these mutations could contribute to reduced mGluR1
activity in vivo.
F122L is located in ‘helix B’ of the mGluR1 ligand binding
domain 1 (LB1), according to the published crystal structure of this
region [1]. We therefore speculate that this mutation influences
ligand binding or, alternatively, interferes with the activation of the
receptor upon ligand binding, as suggested for an experimentally
induced mutation at residue 120, I120A [44]. The N-terminal
region of intracellular loop 2 contains the well-characterized
‘DRY’ motif critical for G protein-coupling in Family A GPCRs
[45]. The location of A683E in this same region indicates that it is
highly likely to influence the mGluR1-G protein interaction.
Furthermore, the introduction of a negatively charged amino acid
by the mutation, and therefore capacity to form strong
electrostatic interactions, is a substantial change at the molecular
level. P970L and P1015A are both present in the intracellular C-
terminal tail, and as such may also play a role in G protein
coupling, probably indirectly via a conformational change in
protein structure. Indeed, evidence for Gbc interaction with the
C-terminal tail of mGluR7 has been published [46].
Mutation P1014S appears to affect the capacity of the receptor
to be optimally expressed at the cell surface. Its intracellular
localization and potential mechanisms of impaired trafficking are
still to be investigated. Notably, this amino acid change did not
completely abolish receptor expression, indicating partial retarda-
tion of receptor trafficking and/or a relatively subtle effect on
Figure 3. Functional analysis and relative plasma membrane expression of mGluR1 mutants in COS-7 cells. Cells transiently expressing
mGluR1, wild-type (WT) or possessing the different mutations as indicated, were assayed for Quisqualate-induced inositol phosphate production
using the IP-One assay (a) or plasma membrane expression using ELISA with anti-mGluR1 antibody on intact cells (b). With the IP-One assay, cells
were stimulated with Quisqualate (10 mM) for 45 minutes and data were normalized to percentage of Quisqualate-induced IP1 production in cells
expressing mGluR1-WT (a). Similarly, the ELISA signals were normalized to percentage of plasma membrane expression of the mGluR1-WT (b). Data
are Mean 6 SEM of four independent experiments carried out in triplicate. *** P,0.001, ** P,0.01, * P,0.05, ns P.0.05.
doi:10.1371/journal.pone.0032849.g003
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receptor folding that may in turn contribute to receptor instability
at the membrane. In the utilized in vitro system, the reduced
expression appears not to be substantial enough to exceed receptor
reserve at the plasma membrane and is therefore not reflected in
reduced signalling output from the receptor population under
examination. This is not an unusual phenomenon for GPCRs that
often only require a fraction of receptors to be occupied in order to
achieve maximal signalling efficacy, the level of which will change
for different agonists and for different cellular backgrounds [47].
However, this result does point to the possibility that, by
influencing receptor folding and/or trafficking, this amino acid
change may contribute to suboptimal receptor function. The result
for Y632H is inconclusive, due to high inter-experimental
variability. Whether this reflects subtle changes in the cellular
milieu affecting the expression of this mutant is unclear, but hints
at further complexity of the receptor system. No significant
functional effect was observed for the P729T polymorphism.
The interpretation of these in vitro data should also take into
account the fact that the mutations occurred in the heterozygous
state. Their effect in vivo could be mitigated by the availability of
normal copies of the protein which may be sufficient for receptor
activity, as discussed above in the context of reduced membrane
expression of the P1014S mutant. On the other hand, the mutants
can interfere with the function of the wild-type protein present in
the same cells, by exerting a dominant negative effect on
dimerization and/or trafficking of the receptor, reviewed in [48].
Unlike the recently reported sequencing data in sporadic
schizophrenia [40–42], none of the changes detected in this study
had arisen de novo. Our primary analysis was not biased towards
familial cases, yet all 5 GRM1 mutations that could be checked for
segregation were shown to be inherited, and four of these occurred
in families affected by a range of neuropsychiatric conditions not
limited to psychotic illness. A commonality of individual genes and
pathways, conferring susceptibility to different neurodevelopmen-
tal disorders, has emerged from recent studies of schizophrenia,
autism spectrum disorders, intellectual deficit and epilepsy [42,49–
55]. In the case of mGluR1, in vitro experiments and studies of
animal models point to possible involvement in anxiety, depres-
sion, epilepsy, and drug addiction and alcoholism, reviewed in
[56–58]. Our findings support such a role.
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